HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting 2024

HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting 2024

HONG KONG, Oct 25, 2024 – (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®…
Read More

Zaļā Josta - Reklāma